Literature DB >> 4730175

The evaluation of cancer control measures.

D A Boyes, J Knowelden, A J Phillips.   

Abstract

The assessment of a screening procedure falls into two parts. The first is the development of a test and the establishment of criteria of specificity and sensitivity. The second stage is that of the application of the test to the general population, demanding attention to the natural history of the disease and to the usefulness and simplicity of the test itself. The decision to organize a screening programme has usually to be taken on the basis of incomplete information and in the setting of a population subjected to constant change. It is the hope of the Committee on Cancer Prevention and Detection of the UICC that the conclusions from the Symposium will prove helpful to all who face such decisions.

Entities:  

Mesh:

Year:  1973        PMID: 4730175      PMCID: PMC2008882          DOI: 10.1038/bjc.1973.127

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  Screening for early detection of cancer and heart disease.

Authors:  S Shapiro
Journal:  Bull N Y Acad Med       Date:  1975-01

Review 2.  Efficacy of cervical cancer screening.

Authors:  F Pettersson
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

3.  Editorial: Cervical cancer screening programs: a pathologist's viewpoint.

Authors:  G H Anderson
Journal:  Can Med Assoc J       Date:  1976-06-05       Impact factor: 8.262

4.  Screening high-risk populations: a challenge to primary medical care.

Authors:  D M Kessner
Journal:  J Community Health       Date:  1976

5.  Mammograms and Mortality: How Has the Evidence Evolved?

Authors:  Amanda E Kowalski
Journal:  J Econ Perspect       Date:  2021

6.  Cervical cancer in the screening era: who fell victim in spite of successful screening programs?

Authors:  B Folke Pettersson; Kristina Hellman; Roxane Vaziri; Sonia Andersson; Ann-Cathrin Hellström
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.